Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection-Reference-Cited by-同舟云学术

Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection

Published:2017-07-25 Issue:2 Volume:17 Page:
ISSN:1871-5265
Container-title:Infectious Disorders - Drug Targets
language:en
Short-container-title:IDDT

Author:

Ahmed Ossama A.¹,Kaisar Hany H.¹,Hawash Nehad²,Samir Hossam¹,Shabana Sherif S. T.¹,Hassan A. Fouad Mohamed¹,Rizk Fatma³,Abd-Elsalam Sherief²

Affiliation:

1. Department of Internal Medicine, Ain Shams University, Faculty of Medicine, Cairo, Egypt

2. Tropical Medicine & Infectious Diseases Department, Tanta University, Faculty of Medicine, Tanta, Egypt

3. Physiology Department, Tanta University, Faculty of Medicine, Tanta, Egypt

Publisher

Bentham Science Publishers Ltd.

Subject

Microbiology (medical),Pharmacology,Molecular Medicine,General Medicine

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study;Medicine;2023-10-27

2. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients;Medicine;2023-07-14

3. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital;Tropical Medicine and Infectious Disease;2023-01-30

4. Diagnostic Accuracy of Red Cell Distribution Width to Platelet Ratio for Detection of Liver Fibrosis Compared with Fibroscan in Chronic Hepatitis B Egyptian patients;The Open Biomarkers Journal;2022-10-12

5. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study;Endocrine, Metabolic & Immune Disorders - Drug Targets;2022-01